MENU
Showcases Stock ranks Forex

Cti Biopharm Corp (CTIC)
9.095  0.005 (0.06%) 06-23 15:58
Open: 9.1 Pre. Close: 9.09
High: 9.1 Low: 9.09
Volume: 5,558,437 Market Cap: 1,199(M)
Stock Technical Analysis
Overall:     
Target: Six months: 10.63
One year: 12.41
Support: Support1: 8.99
Support2: 8.92
Resistance: Resistance1: 9.10
Resistance2: 10.63
Pivot: 9.07
Moving Averages: MA(5): 9.09
MA(20): 9.06
MA(100): 6.15
MA(250):
MACD: MACD(12,26): 0.39
Signal(12,26,9): 0.52
%K %D: %K(14,3): 92.86
%D(3): 94.44
RSI: RSI(14): 83.72
52-Week: High: 9.1
Low: 4.01
Change(%): 28.1
Average Vol(K): 3-Month: 5840
10-Days: 3874
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 9.107 - 9.15 9.15 - 9.19
Low: 8.976 - 9.027 9.027 - 9.075
Close: 9.018 - 9.096 9.096 - 9.17
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ CTIC ] has closed below upper band by 15.8%. Bollinger Bands are 95.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Stock chart
Stock News
Tue, 30 May 2023
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders - Yahoo Finance

Tue, 16 May 2023
CTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go Through (CTIC) - Seeking Alpha

Wed, 10 May 2023
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B - Yahoo Finance

Wed, 10 May 2023
CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to ... - Financial Content

Wed, 10 May 2023
Sobi to Acquire CTI BioPharma - PR Newswire

Wed, 10 May 2023
CTI BioPharma Stock Soars on Deal to Be Acquired for $1.7 Billion - Barron's

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 131.88
Shares Float (M) 99.89
% Held by Insiders 5.50
% Held by Institutions 83.29
Shares Short (K) 11270
Shares Short Prior Month (K) 12170
Stock Financials
EPS -0.540
Book Value (p.s.) -0.190
Profit Margin -91.38
Operating Margin -73.54
Return on Assets (ttm) -28.6
Return on Equity (ttm)
Qtrly Rev. Growth 950.8
Gross Profit (p.s.) 0.382
Sales Per Share 0.575
EBITDA (p.s.) -0.406
Qtrly Earnings Growth
Operating Cash Flow (M) -82.31
Levered Free Cash Flow (M) -85.26
Stock Valuation
PE Ratio -16.84
PEG Ratio
Price to Book value -47.87
Price to Sales 15.83
Price to Cash Flow -14.57
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android